For agreement periods beginning on January 1, 2025, and in subsequent years, CMS calculates the population adjustment to the historical benchmark. At 425.662(b) introductory text, we proposed to remove the phrase health equity benchmark adjustment and add in its place the phrase population adjustment. At 425.662(b)(2), and we proposed to remove the phrase Calculates the HEBA scaler and add in its place the phrase Calculates a scaler. At 425.662, we proposed to revise paragraph (b)(3) to read as follows: Determines the ACO's eligibility for the population adjustment based on the proportion of the ACO's assigned beneficiaries for the performance year who are enrolled in the Medicare Part D low-income subsidy (LIS) or dually eligible for Medicare and Medicaid
Tirzepatide: The Dual Incretin Receptor Agonist Tirzepatide has revolutionized metabolic therapy as the first dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA
Before starting peptide therapy, patients should go into the consultation prepared with key questions
This makes it a promising candidate for: Neurological recovery Cognitive function improvement Mental clarity Joint and Muscle Recovery Anecdotally and in clinical trials, BPC-157 has been reported to aid in the recovery of strained muscles and damaged joints, accelerating both recovery and healing
However, the intent and effect of these respective sections are distinct and therefore the proposed revisions reflect a separate rationale and methodology
